//@产业链观察:回复@产业链观察:转发。$益方生物-U(SH688382)$ 至少确定了在该领域的领先地位与入场券。至于股市波动无法预料,当然我也非常不认同目前的估值水平。
刚刚$益方生物-U(SH688382)$ 公布Session PO.CT02.02 - Phase II Clinical Trials 2/CT246 / 5 - Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer:网页链接
Gar...